State Drug Administration approves application for registration of import of Pago films

pulmonary arterial hypertension is a disease of abnormally elevated blood pressure in the pulmonary arteries caused by known or unknown causes, characterized by vascular spasms, endometrium hyperplasia, mid-layer hypertrophy, outer membrane hyperplasia, in situ thrombosis, inflammation of varying degrees, and clumps of changesrecently, the StateMedicines(http://Regulatory Authority approved the department of the Sipubag tablet (Selexipag tablets) import registration application, for the treatment of pulmonary hypertensionabout slupag tabletsSilupag tablets is an oral effective, highly selective and long-lasting non-protaglandin proshomo receptor (IP receptor) agonist that can improve the injury of endothelial endothelial dependence diastomy, and may inhibit the proliferation of human pulmonary smooth muscle cells, the thickening of the pulmonary blood vessel wallcompared with theof the procyclopinedrug(http:// which is already on the market for the treatment of pulmonary hypertension, schipperis is the first oral formulation to improve patient complianceslupagro tablets are easy to use, avoid intravenous injection site reactions, avoid inhaling agent-type throat irritation and coughDivision to step up the approval of the review as a clinically urgently needed species, included in the priority review processOn December 7, the State Drug Administration approved the import registration of the product for the treatment of pulmonary hypertension to delay the progression of the disease and reduce the risk of hospitalization due to pulmonary hypertension